- Home
- WGRX vs AVTX Comparison
WGRX vs AVTX Comparison
Compare WGRX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- AVTX
- Stock Information
- Founded
- WGRX 2022
- AVTX 2011
- Country
- WGRX United States
- AVTX United States
- Employees
- WGRX N/A
- AVTX N/A
- Industry
- WGRX Other Pharmaceuticals
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- AVTX Health Care
- Exchange
- WGRX Nasdaq
- AVTX Nasdaq
- Market Cap
- WGRX 66.1M
- AVTX 57.4M
- IPO Year
- WGRX 2025
- AVTX 2015
- Fundamental
- Price
- WGRX $0.91
- AVTX $6.66
- Analyst Decision
- WGRX
- AVTX Strong Buy
- Analyst Count
- WGRX 0
- AVTX 7
- Target Price
- WGRX N/A
- AVTX $31.00
- AVG Volume (30 Days)
- WGRX 2.3M
- AVTX 127.8K
- Earning Date
- WGRX 08-11-2025
- AVTX 08-11-2025
- Dividend Yield
- WGRX N/A
- AVTX N/A
- EPS Growth
- WGRX N/A
- AVTX N/A
- EPS
- WGRX N/A
- AVTX N/A
- Revenue
- WGRX $28,992,274.00
- AVTX $441,000.00
- Revenue This Year
- WGRX N/A
- AVTX N/A
- Revenue Next Year
- WGRX N/A
- AVTX N/A
- P/E Ratio
- WGRX N/A
- AVTX N/A
- Revenue Growth
- WGRX N/A
- AVTX N/A
- 52 Week Low
- WGRX $0.75
- AVTX $3.39
- 52 Week High
- WGRX $7.04
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- AVTX 70.62
- Support Level
- WGRX N/A
- AVTX $6.21
- Resistance Level
- WGRX N/A
- AVTX $6.89
- Average True Range (ATR)
- WGRX 0.00
- AVTX 0.49
- MACD
- WGRX 0.00
- AVTX 0.09
- Stochastic Oscillator
- WGRX 0.00
- AVTX 80.71
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).